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Statistical power is one of the major concerns in genetic association studies. Related individuals such as twins are valuable samples
for genetic studies because of their genetic relatedness. Phenotype similarity in twin pairs provides evidence of genetic control over
the phenotype variation in a population.The genetic association study on human longevity, a complex trait that is under control of
both genetic and environmental factors, has been confronted by the small sample sizes of longevity subjects which limit statistical
power. Twin pairs concordant for longevity have increased probability for carrying beneficial genes and thus are useful samples for
gene-longevity association analysis.We conducted a computer simulation to estimate the power of association study using longevity
concordant twin pairs. We observed remarkable power increases in using singletons from longevity concordant twin pairs as cases
in comparison with cases of sporadic proband. A similar power would require doubled sample sizes for fraternal twins than for
identical twins who are concordant for longevity suggesting that longevity concordant identical twins are more efficient samples
than fraternal twins. We also observed an approximate of 2- to 3-fold increase in sample sizes needed for longevity cutoff at age 90
as compared with that at age 95. Overall, our results showed high value of twins in genetic association studies on human longevity.
1. Introduction
Complex phenotypes such as human longevity are associated
withmultiple genetic and environmental factorswith perhaps
the majority of them having low to modest effects [1]. As
such, the power issue has been a crucial concern in genetic
association studies. Although a desired statistical power can
always be achieved by increased sample sizes, there can
be many factors including the laboratory cost that easily
limit the scale of a study. This is especially true for the
currently still expensive genomic analysis, for example, the
genome sequencing technologies. Twins are special samples
that have made remarkable contribution to human genetic
studies due to their genetic and environmental sharing. In
genetic epidemiology, the popular classical twin design has
beenwidely used in estimating the genetic and environmental
components in the variation of disease phenotypes or traits
[2]. For example, using Danish twins, the genetic contribu-
tion to human longevity has been estimated as about 25%
[3, 4]. The low heritability and the complex nature of human
longevity make genetic association study on the trait low
powered. In the literature, the search for genes associatedwith
longevity has continued over many decades with only one
gene, APOE, being conclusively confirmed.
Because of their genetic relatedness, twin pairs con-
cordant for longevity are enriched for carrying beneficial
genes and thus association studies using singletons from
longevity concordant twin pairs should have increased power
in comparisonwith using sporadic longevity individuals.This
paper assesses and explores the power advantage for the use
of longevity concordant twin pairs by computer simulation.
The simulation is based on a proportional hazard assumption
and makes use of the recent life table data of the Danish
population. Lifespan data will be generated for identical or
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Figure 1: The concordant design and the ordinary case-control design for gene-longevity association study. The red frame represents
concordant twin design in which singletons from longevity twin pairs (blue) are collected as cases. In contrast, the red frame is the ordinary
case-control design in which sporadic longevity cases (blue) are sampled. Both designs use young subjects in the middle (orange) as controls.
Table 1: Power estimates for additive effects using longevity concordant MZ twins.
Relative risk 90+ 95+
100 200 300 500 800 100 200 300 500 800
MAF = 0.05
0.5 0.95 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.46 0.78 0.90 0.99 1.00 0.94 1.00 1.00 1.00 1.00
0.8 0.21 0.40 0.53 0.75 0.92 0.54 0.84 0.95 1.00 1.00
0.85 0.13 0.22 0.32 0.49 0.69 0.31 0.58 0.72 0.93 0.99
0.9 0.09 0.12 0.17 0.23 0.34 0.14 0.29 0.35 0.59 0.74
0.95 0.06 0.06 0.08 0.10 0.13 0.06 0.10 0.12 0.19 0.25
MAF = 0.1
0.5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.73 0.95 0.99 1.00 1.00 0.99 1.00 1.00 1.00 1.00
0.8 0.37 0.62 0.80 0.96 1.00 0.80 0.98 1.00 1.00 1.00
0.85 0.21 0.39 0.52 0.76 0.92 0.51 0.83 0.94 0.99 1.00
0.9 0.11 0.19 0.27 0.41 0.56 0.25 0.44 0.59 0.81 0.96
0.95 0.06 0.07 0.11 0.13 0.19 0.08 0.14 0.17 0.30 0.38
MAF = 0.2
0.5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.92 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.8 0.58 0.87 0.96 1.00 1.00 0.96 1.00 1.00 1.00 1.00
0.85 0.34 0.61 0.77 0.94 0.99 0.78 0.96 1.00 1.00 1.00
0.9 0.19 0.32 0.42 0.61 0.81 0.43 0.66 0.84 0.96 1.00
0.95 0.09 0.09 0.13 0.21 0.30 0.13 0.20 0.29 0.46 0.62
MAF = 0.5
0.5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.98 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.8 0.74 0.96 0.99 1.00 1.00 0.99 1.00 1.00 1.00 1.00
0.85 0.48 0.79 0.91 0.99 1.00 0.87 0.99 1.00 1.00 1.00
0.9 0.22 0.43 0.57 0.81 0.95 0.53 0.82 0.95 1.00 1.00
0.95 0.08 0.13 0.17 0.25 0.41 0.16 0.30 0.40 0.61 0.82
Power estimates over the lines are acceptable.
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Table 2: Power estimates for dominant effects using longevity concordant MZ twins.
Relative risk 90+ 95+
100 200 300 500 800 100 200 300 500 800
MAF = 0.05
0.5 0.93 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.45 0.73 0.89 0.98 1.00 0.91 1.00 1.00 1.00 1.00
0.8 0.21 0.38 0.51 0.72 0.90 0.53 0.81 0.94 0.99 1.00
0.85 0.14 0.22 0.30 0.46 0.64 0.30 0.51 0.69 0.90 0.98
0.9 0.08 0.12 0.15 0.23 0.32 0.16 0.23 0.36 0.56 0.71
0.95 0.06 0.07 0.07 0.09 0.12 0.07 0.09 0.12 0.15 0.22
MAF = 0.1
0.5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.67 0.93 0.99 1.00 1.00 0.99 1.00 1.00 1.00 1.00
0.8 0.34 0.57 0.74 0.93 0.99 0.74 0.96 0.99 1.00 1.00
0.85 0.19 0.33 0.46 0.70 0.88 0.47 0.76 0.89 0.99 1.00
0.9 0.11 0.17 0.24 0.34 0.50 0.22 0.38 0.51 0.75 0.93
0.95 0.06 0.08 0.09 0.11 0.16 0.07 0.12 0.17 0.26 0.35
MAF = 0.2
0.5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.84 0.98 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.8 0.46 0.74 0.90 0.99 1.00 0.85 0.99 1.00 1.00 1.00
0.85 0.27 0.48 0.62 0.85 0.97 0.61 0.89 0.97 1.00 1.00
0.9 0.14 0.22 0.32 0.49 0.68 0.32 0.51 0.69 0.89 0.97
0.95 0.08 0.09 0.11 0.15 0.22 0.10 0.16 0.22 0.33 0.46
MAF = 0.5
0.5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.76 0.96 1.00 1.00 1.00 0.98 1.00 1.00 1.00 1.00
0.8 0.38 0.64 0.83 0.97 1.00 0.74 0.95 0.99 1.00 1.00
0.85 0.23 0.41 0.56 0.78 0.93 0.48 0.75 0.91 0.99 1.00
0.9 0.11 0.19 0.28 0.43 0.61 0.25 0.43 0.58 0.81 0.94
0.95 0.06 0.08 0.10 0.13 0.18 0.10 0.13 0.18 0.32 0.42
Power estimates over the lines are acceptable.
monozygotic (MZ) and fraternal or dizygotic (DZ) twin pairs
with power compared between zygosities and across different
experiment setups.
2. Materials and Methods
2.1. Experiment Design. Themost popular experiment design
for genetic association study on human longevity is the case-
control design which samples longevity individuals (e.g.,
centenarians and nonagenarians) as cases and young or
middle aged individuals as controls [5]. The power issue for
the case-control design has been investigated by Tan et al. [6].
The current simulation study focuses on the power advantage
of using singleton twins from twin pairs concordant for
longevity as cases (Figure 1). That is, from each concordant
twin pair reaching certain threshold for longevity (e.g., 90 or
95 in this simulation), only one twin will be taken as case for
genotyping.The controls will be collected as in ordinary case-
control studies from unrelated individuals. With this design,
the final data for analysis contain unrelated cases and controls
with cases collected as singletons from longevity concordant
twin pairs (one from each pair) and controls as unrelated
individuals at age 40–50 years. The study design draws equal
number of cases and controls in the final sample.
2.2.TheDanish Life Table Data. Our simulation of individual
lifespan data is based onDanish population survival informa-
tion, that is, the Danish life table data available from Statistics
Denmark (http://www.statbank.dk/). The current simulation
work used the most recent Danish life table data for period
2012-2013 with life expectancy 78 years for males and 82
years for females. The simulation takes the mean survival
rate over the two sexes. The use of observed population
survival rate avoids imposing any parametric form for the
survival function in the simulation and thus ensures that our
simulated survival data follows survival distribution in a real
population (i.e., the Danish population).
2.3. The Proportional Hazard Model. For a given genetic
variant, for example, single nucleotide polymorphism (SNP),
we assign a frequency parameter 𝑝 and a relative risk
parameter 𝑟 for theminor allele of the SNP.Then the observed
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Table 3: Power estimates for recessive effects using longevity concordant MZ twins.
Relative risk 90+ 95+
100 200 300 500 800 100 200 300 500 800
MAF = 0.05
0.5 — 0.07 0.15 0.26 0.41 0.15 0.47 0.66 0.87 0.99
0.7 — — 0.05 0.10 0.12 — 0.06 0.15 0.26 0.38
0.8 — — — — 0.08 — — — 0.10 0.13
0.85 — — — — 0.07 — — — 0.07 0.10
0.9 — — — — 0.06 — — — — 0.08
0.95 — — — — — — — — — 0.05
MAF = 0.1
0.5 0.25 0.48 0.70 0.88 0.98 0.85 1.00 1.00 1.00 1.00
0.7 0.07 0.13 0.20 0.31 0.47 0.18 0.40 0.57 0.81 0.96
0.8 — 0.08 0.10 0.12 0.19 0.09 0.13 0.23 0.31 0.52
0.85 — 0.06 0.08 0.09 0.12 — 0.11 0.11 0.18 0.30
0.9 — 0.05 0.05 0.05 0.07 — 0.07 0.08 0.08 0.15
0.95 — — 0.05 — 0.06 — 0.05 — 0.07 0.08
MAF = 0.2
0.5 0.90 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.29 0.50 0.68 0.88 0.98 0.75 0.96 1.00 1.00 1.00
0.8 0.13 0.20 0.29 0.45 0.66 0.32 0.55 0.75 0.91 0.98
0.85 0.08 0.12 0.17 0.26 0.38 0.17 0.31 0.40 0.63 0.85
0.9 0.06 0.07 0.10 0.13 0.18 0.08 0.15 0.17 0.26 0.41
0.95 0.05 0.06 0.07 0.06 0.09 0.05 0.09 0.08 0.08 0.12
MAF = 0.5
0.5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.92 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.8 0.51 0.77 0.91 0.99 1.00 0.90 1.00 1.00 1.00 1.00
0.85 0.28 0.47 0.65 0.87 0.97 0.63 0.89 0.98 1.00 1.00
0.9 0.14 0.22 0.31 0.45 0.64 0.26 0.50 0.68 0.87 0.98
0.95 0.06 0.08 0.11 0.14 0.19 0.09 0.16 0.20 0.30 0.46
aPower estimates over the lines are acceptable.
bDashes indicate power estimates <0.05.
population survival rate at any age 𝑥 is a weighted average of
three subpopulations carrying 0, 1, and 2 copies of the minor
allele, respectively [7], that is,
𝑠 (𝑥) = 𝑝
2
𝑠
2
(𝑥) + 2𝑝 (1 − 𝑝) 𝑠
1
(𝑥) + (1 − 𝑝)
2
𝑠
0
(𝑥) . (1)
In (1), 𝑠(𝑥), 𝑠
0
(𝑥), 𝑠
1
(𝑥), 𝑠
2
(𝑥) are survival rate for the total
population and for the three subpopulations at age𝑥; (1 − 𝑝)2,
2𝑝(1 − 𝑝), 𝑝2 are frequencies for corresponding genotypes
following binomial distribution of the minor allele frequency
(MAF), 𝑝. With the proportional hazard assumption, the
hazards of death corresponding to 𝑠
1
(𝑥) and 𝑠
2
(𝑥) can be
expressed as 𝜇
1
(𝑥) = 𝑟𝜇
0
(𝑥) and 𝜇
2
(𝑥) = 𝑟
2
𝜇
0
(𝑥) so that
𝑠
1
(𝑥) = 𝑒
−∫
𝑥
0
𝜇
1
(𝑡)𝑑𝑡
= 𝑒
−∫
𝑥
0
𝑟𝜇
0
(𝑡)𝑑𝑡
= (𝑒
−∫
𝑥
0
𝜇
0
(𝑡)𝑑𝑡
)
𝑟
= 𝑠
0
(𝑥)
𝑟
,
(2)
and likewise, 𝑠
2
(𝑥) = 𝑠
0
(𝑥)
𝑟
2
. With these relationships and for
givenMAF 𝑝 and relative risk 𝑟, (1) can be solved numerically
to obtain a nonparametric estimate of the baseline survival
𝑠
0
(𝑥) and then 𝑠
1
(𝑥) and 𝑠
2
(𝑥) can be calculated and used
for generating individual lifespan. In the simulation, we
introduced a heterogeneity model for the baseline survival
function in order to take into account of the unobserved
factors that also affect individual survival [8].
2.4. Simulating Lifespan. In order to simulate lifespan using
genotype-specific survival, 𝑠
0
(𝑥), 𝑠
1
(𝑥), and 𝑠
2
(𝑥), a genotype
will be randomly assigned to each individual using the
binomial probability of MAF. For MZ twin pairs, this was
first done for one singleton and then the same genotype was
copied to the cotwin. For DZ twin pairs, we started with
independently simulating genotypes for each parent of a twin
pair and assigned genotype for a singleton in a DZ pair by
randomly taking one allele from each parent. This ensures
that two twins within a pair have 50% chance of inheriting an
allele identical by descent (IBD). The lifespan for unrelated
controls was simulated by randomly assigning a genotype
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Table 4: Power estimates for additive effects using longevity concordant DZ twins.
Relative risk 90+ 95+
100 200 300 500 800 1500 100 200 300 500 800 1500
MAF = 0.05
0.5 0.73 0.94 0.98 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.30 0.53 0.71 0.87 0.97 1.00 0.74 0.95 0.99 1.00 1.00 1.00
0.8 0.16 0.23 0.34 0.51 0.72 0.92 0.34 0.56 0.73 0.93 0.99 1.00
0.85 0.10 0.16 0.17 0.31 0.44 0.69 0.20 0.34 0.47 0.70 0.89 0.99
0.9 0.07 0.08 0.12 0.14 0.24 0.37 0.12 0.19 0.25 0.37 0.50 0.77
0.95 0.06 0.05 0.06 0.08 0.09 0.11 0.08 0.08 0.08 0.11 0.14 0.24
MAF = 0.1
0.5 0.92 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.50 0.74 0.90 0.99 1.00 1.00 0.93 0.99 1.00 1.00 1.00 1.00
0.8 0.25 0.44 0.54 0.76 0.92 0.99 0.57 0.83 0.95 1.00 1.00 1.00
0.85 0.15 0.24 0.32 0.48 0.68 0.90 0.32 0.56 0.74 0.92 0.99 1.00
0.9 0.09 0.13 0.17 0.26 0.35 0.64 0.16 0.28 0.36 0.55 0.75 0.96
0.95 0.06 0.06 0.07 0.09 0.12 0.19 0.06 0.11 0.13 0.16 0.26 0.43
MAF = 0.2
0.5 0.97 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.68 0.93 0.99 1.00 1.00 1.00 0.99 1.00 1.00 1.00 1.00 1.00
0.8 0.36 0.63 0.79 0.94 0.99 1.00 0.78 0.98 1.00 1.00 1.00 1.00
0.85 0.24 0.35 0.53 0.75 0.92 1.00 0.51 0.81 0.94 0.99 1.00 1.00
0.9 0.12 0.21 0.29 0.39 0.59 0.84 0.23 0.45 0.61 0.80 0.94 1.00
0.95 0.06 0.08 0.12 0.13 0.19 0.31 0.09 0.14 0.17 0.25 0.44 0.68
MAF = 0.5
0.5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.84 0.98 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.8 0.48 0.79 0.91 0.99 1.00 1.00 0.88 1.00 1.00 1.00 1.00 1.00
0.85 0.30 0.55 0.71 0.88 0.98 1.00 0.67 0.90 0.98 1.00 1.00 1.00
0.9 0.16 0.25 0.38 0.57 0.72 0.95 0.33 0.56 0.74 0.92 0.99 1.00
0.95 0.08 0.09 0.12 0.18 0.25 0.41 0.12 0.18 0.26 0.40 0.58 0.83
aPower estimates over the lines are acceptable.
to each control subject using the binomial distribution of
the minor allele. Subjects at age 40–50 years were selected
as controls. We simulated power for cases from concordant
MZ andDZ twin pairs separately aiming at comparing power
difference between zygosities.
2.5. Statistical Testing and Power Calculation. Since the
samples collected in our simulation design are case-control
samples, the popular Armitage’s trend test [9] was applied for
statistical testing on our simulated samples in each replicate.
Similar test had been used in our previous power simulation
for genetic association studies on human longevity [6, 10].
Power simulation was done for different combinations of
mode of inheritance (additive, dominant, and recessive),
allele frequency (MAF = 0.05, 0.1, 0.2, 0.5), and risk of allele
(𝑟 = 0.5, 0.7, 0.8, 0.85, 0.9, 0.95) and for different sample
sizes of cases (𝑁 = 100, 200, 300, 500, 800, 1500). For each
combination, 𝐾 = 1000 replicates were simulated and
statistical testing was applied to each replicate. With 1000 𝜒2
values obtained from Armitage’s trend test, corresponding
power was calculated as
Power (𝛼 = 0.05) =
∑
𝐾
𝑖=1
𝐼 [𝜒
2
(𝑖) ≥ 𝜒
2
0.05,1
]
𝐾
, (3)
where 𝐼(⋅) is an indicator function for logical expression with
1 if true and 0 if false.
3. Results
In Table 1, we show the power estimates for additive effect of
SNP alleles with different combinations of genetic parameters
(MAF, relative risk) for different sample sizes from concor-
dantMZ twins and for different cutoffs of longevity.With 800
cases aged 95+, the design is able to identify a common SNP
(MAF = 0.5) with a small effect of only 5% reduction of rate
of death (𝑟 = 0.95). For a small sample size of 200 cases aged
over 95 years, the study design has good power (over 0.8) to
capture a common SNP with MAF = 0.5 that reduces hazard
of death by 10% (𝑟 = 0.9); a SNP with lower MAF = 0.1
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Table 5: Power estimates for dominant effects using longevity concordant DZ twins.
Relative risk 90+ 95+
100 200 300 500 800 1500 100 200 300 500 800 1500
MAF = 0.05
0.5 0.72 0.93 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.28 0.47 0.65 0.85 0.97 1.00 0.64 0.91 0.99 1.00 1.00 1.00
0.8 0.15 0.24 0.32 0.48 0.68 0.92 0.32 0.56 0.72 0.91 0.99 1.00
0.85 0.10 0.16 0.16 0.28 0.40 0.66 0.20 0.34 0.45 0.63 0.84 0.98
0.9 0.07 0.08 0.12 0.14 0.20 0.34 0.12 0.16 0.21 0.33 0.49 0.75
0.95 0.05 0.06 0.05 0.07 0.09 0.12 0.07 0.07 0.08 0.11 0.14 0.24
MAF = 0.1
0.5 0.88 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.44 0.71 0.84 0.98 1.00 1.00 0.85 0.99 1.00 1.00 1.00 1.00
0.8 0.18 0.37 0.49 0.69 0.88 0.99 0.49 0.76 0.91 0.98 1.00 1.00
0.85 0.12 0.19 0.30 0.47 0.63 0.88 0.28 0.51 0.69 0.88 0.98 1.00
0.9 0.09 0.14 0.15 0.22 0.33 0.55 0.15 0.23 0.35 0.51 0.70 0.92
0.95 0.06 0.05 0.06 0.07 0.11 0.16 0.07 0.09 0.10 0.15 0.22 0.36
MAF = 0.2
0.5 0.97 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.58 0.84 0.95 1.00 1.00 1.00 0.94 1.00 1.00 1.00 1.00 1.00
0.8 0.28 0.50 0.65 0.86 0.96 1.00 0.64 0.90 0.98 1.00 1.00 1.00
0.85 0.17 0.29 0.36 0.58 0.80 0.97 0.41 0.62 0.80 0.95 0.99 1.00
0.9 0.12 0.14 0.21 0.28 0.43 0.69 0.19 0.31 0.47 0.65 0.84 0.98
0.95 0.06 0.07 0.08 0.10 0.11 0.20 0.08 0.10 0.15 0.21 0.31 0.51
MAF = 0.5
0.5 0.95 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.46 0.77 0.90 0.98 1.00 1.00 0.84 0.98 1.00 1.00 1.00 1.00
0.8 0.25 0.41 0.54 0.76 0.91 1.00 0.46 0.73 0.89 0.99 1.00 1.00
0.85 0.15 0.24 0.34 0.49 0.69 0.90 0.28 0.49 0.65 0.86 0.98 1.00
0.9 0.08 0.12 0.16 0.25 0.35 0.58 0.14 0.25 0.32 0.54 0.70 0.93
0.95 0.05 0.07 0.08 0.09 0.13 0.17 0.06 0.10 0.11 0.17 0.24 0.40
aPower estimates over the lines are acceptable.
and hazard reduction of 15% (𝑟 = 0.85); and a rare SNP with
MAF = 0.05 and hazard reduction of 20% (𝑟 = 0.8). A small
sample of 100 cases aged 95+ is able to detect a common SNP
(MAF = 0.2) with risk reduction of 15% (𝑟 = 0.85). When the
longevity cut-off is set to 90 years, a sample size of 500 to 800
cases is required to achieve comparable power, an increase of
about 3 folds. The power for detecting dominant effect SNPs
using MZ cases (Table 2) is almost comparable with that for
the additive effect SNPs with low MAF in Table 1 although
the difference increases with increasing MAF. Note that, for
dominant effect SNPs, the power starts to decline whenMAF
approaches 0.5. The statistical power is largely reduced for
recessive effect SNPs (Table 3). However, for high MAF SNPs
(𝑝 = 0.5), the design has good power with 500 cases aged
over 95 for 𝑟 = 0.9. Comparable power can be achieved with
only 200 cases for 𝑟 = 0.85. Interestingly, when comparing
power estimates between the two longevity cutoffs (90 and 95
years) for defining cases, we see that the cutoff of 90+ needs 2
to 3 times larger sample sizes to obtain comparable power as
compared with that of 95+, a conclusion that applies to Tables
1 to 3.
Tables 4, 5, and 6 carry power estimates for similar
parameter settings corresponding to Tables 1–3 except that
we added a bigger sample size of 1500 cases considering the
relative ease in sampling DZ thanMZ concordant twin pairs.
The power estimates for DZ twins exhibit similar pattern as
forMZ twins but a 2-3-fold increase in sample size is required
to obtain comparable power for corresponding settings as in
Tables 1–3.
4. Discussions
Using computer simulation, we have estimated statistical
power for a case-control design using singleton cases from
twin pairs concordant for longevity. Different from the ordi-
nary case-control studies that collect sporadic centenarians
as cases, we limit our cutoffs for longevity to 90 and 95
considering rarity of twin pairs concordant for extreme
longevity. It is interesting to compare our power estimates
with those from our previous simulation study on ordinary
case-control design with sporadic nontwin centenarians as
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Table 6: Power estimates for recessive effects using longevity concordant DZ twins.
Relative risk 90+ 95+
100 200 300 500 800 1500 100 200 300 500 800 1500
MAF = 0.05
0.5 — — 0.07 0.13 0.19 0.32 — 0.14 0.26 0.42 0.60 0.89
0.7 — — — 0.05 0.08 0.09 — — 0.05 0.11 0.15 0.28
0.8 — — — — 0.06 0.07 — — — 0.06 0.09 0.12
0.85 — — — — 0.05 0.07 — — — — 0.06 0.07
0.9 — — — — — — — — — — 0.05 0.05
0.95 — — — — 0.05 — — — — — — 0.05
MAF = 0.1
0.5 0.11 0.18 0.32 0.46 0.68 0.91 0.45 0.73 0.91 0.99 1.00 1.00
0.7 0.05 0.07 0.09 0.13 0.23 0.36 0.08 0.17 0.25 0.36 0.57 0.83
0.8 — 0.06 0.07 0.09 0.11 0.16 — 0.07 0.09 0.15 0.26 0.41
0.85 — 0.05 0.06 0.06 0.09 0.09 — 0.07 0.09 0.11 0.14 0.24
0.9 — — 0.06 — 0.06 0.09 — 0.05 — 0.06 0.08 0.10
0.95 — — 0.05 0.05 0.05 0.05 — — 0.05 — 0.06 0.06
MAF = 0.2
0.5 0.51 0.77 0.92 0.99 1.00 1.00 0.99 1.00 1.00 1.00 1.00 1.00
0.7 0.14 0.23 0.36 0.51 0.73 0.93 0.38 0.62 0.82 0.95 1.00 1.00
0.8 0.08 0.12 0.16 0.21 0.33 0.57 0.14 0.24 0.34 0.56 0.76 0.96
0.85 — 0.07 0.10 0.15 0.18 0.30 0.08 0.14 0.19 0.30 0.46 0.71
0.9 0.06 0.06 0.08 0.07 0.11 0.13 0.06 0.08 0.12 0.14 0.20 0.35
0.95 — 0.05 0.05 0.05 0.05 0.08 0.05 0.06 0.06 0.08 0.08 0.10
MAF = 0.5
0.5 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.7 0.68 0.90 0.99 1.00 1.00 1.00 0.98 1.00 1.00 1.00 1.00 1.00
0.8 0.28 0.49 0.65 0.86 0.96 1.00 0.64 0.90 0.98 1.00 1.00 1.00
0.85 0.16 0.26 0.38 0.57 0.75 0.95 0.35 0.62 0.78 0.94 0.99 1.00
0.9 0.09 0.12 0.20 0.27 0.39 0.62 0.16 0.27 0.38 0.56 0.76 0.97
0.95 0.07 0.07 0.08 0.09 0.12 0.17 0.08 0.09 0.12 0.18 0.27 0.44
aPower estimates over the lines are acceptable.
bDashes indicate power estimates <0.05.
cases [6]. Even with lowered threshold for longevity at age 95,
the concordant MZ twin design is able to achieve equivalent
power as in ordinary case-control design with centenarian
cases for similar or even smaller sample sizes (comparing
Tables 1–3 with Tables 1–3 in Tan et al. [6]).With an age cutoff
at 90 years, our power estimates can be compared to those
in our previous simulation which also simulated power for
using nonagenarians as cases (Tables 4–6 in Tan et al. [6]).
For comparable power estimates, the case-control designwith
cases as sporadic nonagenarians would need much larger
sample sizes compared with using nonagenarian cases from
concordant twin pairs (3-4 folds for MZ and about 2 folds
forDZ twins). Overall, our results revealed remarkable power
advantage in using longevity concordant twins over ordinary
case-control design.
Comparing the power estimates in Tables 1–3 with those
in Tables 4–6, we observe that a power advantage in using
cases of MZ twins over cases of DZ twins with the latter
requiring almost doubled sample sizes to reach equivalent
power. Although relatively lower powered, the DZ twin pairs
are actually the same as sibling pairs in genetic sharingmean-
ing that, in practice, concordant DZ twins can be replaced by
concordant sibling pairs making sample collection easier and
more feasible. On the other hand, when laboratory cost for
genotyping is amajor concern (such as genome-wide analysis
or next-generation sequencing), MZ cases are the best choice
as they help to maintain good power but with the lowest
sample sizes.
Another interesting finding is the power difference
between the two age cutoffs. For both MZ and DZ twins,
approximately 2 to 3 times larger sample sizes are needed for
cases of 90+ as compared with cases of 95+. For example,
for an additive effect allele with MAF = 0.5 and 𝑟 = 0.9,
the power for 300 cases of 95+ is equivalent to that for 800
cases of 90+ in both Tables 1 and 2. The large difference in
power is understandable considering the very high selection
pressure going on during this age interval. Survival data
from the Danish 1905 birth cohort showed equal chances
for surviving from birth to age 92 as from age 92 to 100
[11]. As a trade-off for power advantage, the extremely high
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survival selection also adds difficulty in collecting concordant
twin pairs aged 95+. The study design should always balance
sampling feasibility, power, and age cutoff.
The power advantage in using singleton cases from
longevity concordant twin pairs is purely due to increased
likelihood for carrying longevity-linked genetic variants.
For the same sample size, this study design has the same
genotyping cost as an ordinary case-control study but with
much higher power. In other words, acceptable power can
be achieved with lower cost. This is especially important as
current techniques for genomic analysis, for example, the
microarray and the next-generation sequencing techniques,
are still expensive. Although this study focuses only on
power advantage of using twins in longevity studies, our
results should also reflect similar situation in human disease
studies, that is, using disease concordant twins as cases.More-
over, although our current study focuses on advantage of
concordant MZ twins in gene-longevity association studies,
MZ twin pairs discordant for longevity or diseases are also
useful samples for looking for environmental factors. Taking
all together, the unique samples of twins will have a good
potential in contributing to the molecular genetic studies of
human complex diseases and traits.
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